SWOT Analysis for CytomX Therapeutics Inc

MACD Crossover Above Signal Line
Relative Outperformance versus Industry over 1 Week
Significant (over 30%) distance from 52 week high
PE less than Industry PE
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
MACD crossed above signal line previous end of day
Increasing Revenue every quarter for the past 2 quarters
Annual Net Profits improving for last 2 years
Increasing profits every quarter for the past 2 quarters
Top Gainers
Stock with Low PE (PE < = 10)
Biggest Price Gainers from Open

Stocks with Quarter Change % less than Industry
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Lowest Momentum Scores (Technical Scores)
Highest fall from 52 Week High
Near 52 Week Low
Low Piotroski Score : Companies with weak financials
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
Stocks Underperforming their Industry Price Change in the Quarter